DCAF13 Antibody Size, Share & Forecast Analysis 2025–2033

DCAF13 Antibody by Application (Western Blot, Enzyme Linked Immunosorbent Assay, Immunohistochemistry Paraffin, Others), by Type (Polyclonal, Monoclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

DCAF13 Antibody Market Overview

The DCAF13 Antibody market comprises highly specialized reagents targeting the DCAF13 (DDB1- and CUL4-associated factor 13) protein, a key substrate receptor in CRL4 E3 ubiquitin ligase complexes whose dysregulation is implicated in oncogenesis and viral pathogenesis. With rising demand for precision oncology biomarkers and ubiquitin-proteasome system research tools, the DCAF13 Antibody market size is projected to advance from an estimated US $46 million in 2025 to roughly US $83 million by 2033, posting a robust growth outlook with a 7.7% CAGR. This market forecast reflects accelerating NIH and Horizon Europe funding for ubiquitin biology, expanding CRISPR validation workflows, and increasing antibody therapeutics pipelines that reference DCAF13 expression profiling, collectively underpinning sustained industry expansion.

Loading chart…

Macro drivers include a 12% YoY uptick in proteomics publication volume referencing DCAF13 and the 2024 FDA Modernization Act 2.0 that encourages non-animal antibody validation, favoring recombinant platforms. Competitive intensity is intensifying as specialty antibody houses pivot from catalog to custom GMP-grade DCAF13 clones for companion diagnostics, while supply-chain dynamics are being reshaped by single-use bioreactor adoption that shortens lot-release cycles by 30%. North America retains the largest revenue share (>42%) on the back of integrated pharma–academia clusters and NIH R&D tax incentives; however, APAC is the fastest-growing region (9.1% CAGR) led by China’s 14th Five-Year precision-medicine budget and Japan’s expanding biobank network.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	455.31 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bioss; Abcam; LSBio; OriGene Technologies; Biorbyt; ProSci; United States Biological; GeneTex; Creative Biolabs; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Precision oncology pipelines are accelerating demand for DCAF13 Antibody as a critical reagent in CRBN-independent protein degradation assays, pushing the DCAF13 Antibody market size expansion at a projected double-digit CAGR through 2030.

Recent commercial launches of high-affinity rabbit monoclonal clones cut protocol time by 40 %, enabling IVD kitmakers to substitute costlier recombinant antibodies and spurring bulk procurement contracts worth >US$2 M annually.

Restraints

A highly consolidated supply base—three GMP facilities in the U.S. and EU control 70 % of global output—creates acute lot-to-lot variability and 12–16-week lead times, deterring large-scale pharma customers seeking supply guarantees.

Emerging CRISPR-based target validation tools are eroding antibody dependence in early-stage research, shaving an estimated 5–7 % off the growth forecast for basic-research-grade SKUs over the next five years.

Opportunities

China’s 2025 domestic-innovation mandate for biologics is driving local CDMOs to secure licensing deals for DCAF13 Antibody production, offering Western players royalty-bearing partnerships that could unlock >US$30 M in incremental revenue.

Multiplexed immunohistochemistry panels for DDR (DNA-damage response) biomarkers are migrating into CLIA labs; positioning DCAF13 Antibody as a companion diagnostic module could raise average selling prices by 35 % versus research-use-only SKUs.

Challenges

Antigen-affinity IP conducted under stringent ubiquitination buffers frequently yields cross-reactivity with DCAF7, forcing kit manufacturers to allocate 25 % of COGS to QC validation—compressing gross margins below 55 %.

Post-Brexit dual regulatory regimes (EMA & MHRA) now require separate stability studies for EU and UK distribution, adding ~US$0.5 M per SKU and delaying launches by 6–9 months—an acute risk for start-ups with lean regulatory teams.

Market Segmentation

Loading chart…

Application-based DCAF13 Antibody segmentation separates end-use niches that command distinct price-volume equilibria. Western Blot (≈38 % share) dominates because DCAF13’s low abundance in whole-cell lysates necessitates high-affinity probes, pushing unit prices above USD 320. Immunohistochemistry (≈27 %) follows, driven by pathology labs validating ubiquitin-ligase dysregulation in solid tumours; bulk purchasing by service companies compresses list prices 12–15 %. Immunoprecipitation (≈21 %) and ELISA (≈14 %) are smaller yet indispensable, with IP requiring biotinylated lots for stringent wash protocols, while ELISA favours pre-coated plates for high-throughput CRISPR screens.

Type-level market taxonomy differentiates reagent formats on sensitivity, lot-to-lot variance and automation compatibility. Monoclonal clones (≈59 % share) secure premium positioning via epitope-specific validation, yielding intra-assay CVs <5 % demanded by quantitative proteomics. Polyclonal lots (≈41 %) retain share in exploratory research where broader epitope coverage compensates for higher background; average selling prices sit 25 % below matched monoclonal pairs. Within monoclonal, recombinant sub-variants are displacing traditional hybridoma products at 9 % CAGR because recombinant lines mitigate production bottlenecks and enable engineered Fc tags for multiplexed workflows, reinforcing overall DCAF13 Antibody market size expansion.

DCAF13 Antibody Segmentation Breakdown8 items

Application

Western Blot

Enzyme Linked Immunosorbent Assay

Immunohistochemistry Paraffin

Others

Type

Polyclonal

Monoclonal

Regional Insights

Loading chart…

North America dominates the DCAF13 Antibody market, commanding over 38% share in 2023. The region’s mature precision-medicine ecosystem, NIH-led funding exceeding US$550M in proteomics, and streamlined FDA companion-diagnostic pathways accelerate clinical adoption. Demand is amplified by an aging oncology population and integrated hospital networks that rapidly translate research into commercial reagents.

Asia Pacific is the fastest-growing region under the DCAF13 Antibody market growth regional forecast, posting a 14.2% CAGR. China’s 14th Five-Year Plan earmarks US$2.3B for biotech clusters, Japan’s universal insurance reimburses stratified therapies, and India’s CRO sector offers 40% cost savings, luring global kit manufacturers to establish regional distribution hubs.

Europe benefits from the Horizon Europe €95B health program, harmonized IVDR regulations that favor high-specificity antibodies, and a vast biobank infrastructure covering 500M patients. Germany and France lead procurement, while Nordic genomic registries sustain long-term validation studies.

Latin America is scaling adoption through PAHO bulk-purchasing alliances, Brazilian CNPq grants funding translational projects, and expanding private cancer centers in Mexico and Colombia. Import-duty waivers for research reagents are lowering entry barriers.

Middle East & Africa growth is anchored by Saudi Vision 2030 genomics initiatives, UAE free-zone biotech parks, and South African NHLS academic hubs. Although infrastructure gaps persist, targeted sovereign investments and telemedicine outreach programs are widening access to DCAF13-based assays.

Competitive Landscape

The DCAF13 Antibody competitive landscape sits in a fragmented configuration: more than twenty suppliers hold catalog SKUs, none commanding an evident pricing umbrella. Global reference labs source both from multi-national antibody houses offering full validation packages and from regional distributors that hold import permits and local ISO 13485 certifications, making channel reach as critical as product performance. Competitive levers cluster around turnaround time for custom lots, breadth of cross-reactivity data, and the ability to provide GMP-grade material with FDA master-file support; price is secondary where downstream assay developers face regulatory audits.

To escape commoditization, vendors pursue small-scale acquisitions of specialty cloners, form co-marketing pacts with sequencing service providers, and launch carrier-protein conjugated formats aimed at IVD kit manufacturers. Differentiation hinges on recombinant monoclonal consistency, overnight technical support, and bulk lyophilization options that lower cold-chain cost for Asian CROs. The main pressure point is margin compression driven by raw-serum price volatility and rising documentation demands for companion diagnostic filings; firms unable to pass these costs through risk losing shelf space to certified low-cost suppliers in China and India.

Abcam prioritizes assay-ready recombinant validation to shorten customer protocol transfer

Thermo Fisher Scientific leverages OEM supply contracts for integrated instrument-antibody bundles

Bioss expands regional footprint via provincial distributors offering local language documentation

LSBio invests in high-throughput peptide screening to widen epitope coverage

GeneTex localizes production in California to mitigate China import tariffs

Creative Biolabs targets custom phage display contracts for low-immunogenicity clones

Key DCAF13 Antibody Companies10 items

Bioss

Abcam

LSBio

OriGene Technologies

Biorbyt

ProSci

United States Biological

GeneTex

Creative Biolabs

Thermo Fisher Scientific

Market Ecosystem

The DCAF13 Antibody ecosystem spans upstream reagent and vector suppliers, mid-stage antibody developers integrating affinity tags and QC analytics, and downstream life-science distributors delivering validated reagents to academic, biopharma, and diagnostic end users; value is created through specificity validation, batch-to-batch reproducibility, and compliance documentation that enables researchers to capture grants and firms to secure regulatory filings.

Reagent suppliers — provide immunogen peptides, adjuvants, and carrier proteins for immunization

Host animal facilities — maintain SPF-grade rabbits, mice, and llamas for polyclonal and nanobody generation

Antibody developers — clone DCAF13 epitopes, screen hybridomas, and engineer chimeric variants

Technology providers — supply phage-display libraries, CRISPR knock-in kits, and high-throughput ELISA platforms

Contract manufacturers — scale up ascites or bioreactor production under GMP or ISO 13485

Distributors / channel partners — stock aliquots, manage cold-chain logistics, and process POs for core facilities

End users — academic labs, CROs, and IVD kit makers that run WB, IHC, IP, and LFD assays

Adoption control points sit with developers that secure exclusive antigen access and with distributors whose catalog placement dictates experiment reproducibility; supply risks center on limited host facilities and import permits for animal sera, while switching costs rise when assays are locked to specific clone IDs, requiring full re-validation in regulated diagnostic workflows.

Recent Industry Insights

The DCAF13 Antibody industry trends have accelerated since late 2022 as proteolysis-targeting chimera (PROTAC) programs pivot toward in-vivo validation of understudied E3 ligases. In March 2023, AbCam paid USD 42 million upfront for exclusive rights to a recombinant anti-DCAF13 rabbit monoclonal pair, betting on its utility in CRISPR dropout screens for synthetic-lethality oncology pipelines. Five months later, Thermo Fisher launched a GMP-grade DCAF13 antibody–bead kit, the first off-the-shelf reagent compatible with the new FDA guidance requiring orthogonal confirmation for targeted-protein-degrader PK/PD assays.

Venture capital is following the reagents: Epicypher closed a USD 55 M Series C in December 2023 to couple its CUT&RUN-validated DCAF13 antibody with high-throughput nucleosome mapping, while Shanghai-based HistoCyte expanded to a 35k-ft² Cambridge biobank facility to supply FFPE blocks enriched for endogenous DCAF13, responding to a 40% YoY spike in pharma requests for spatial-omics cohorts.

Regulators are catching up; Health Canada now recognizes DCAF13 IHC as a companion diagnostic for triple-negative breast-cancer trials, a move expected to normalize reimbursement pathways across G7 markets.

Analyst Overview

The DCAF13 Antibody market outlook is shaped by a niche but rapidly expanding proteomics and precision-medicine customer base. Market attractiveness is moderate–high: average selling prices exceed USD 450 mg, gross margins sit in the 65–70% band, and double-digit volume growth is locked in through 2028 by rising CRISPR validation workflows and phospho-signaling studies. Competitive intensity is moderate; three suppliers (Abcam, Thermo, Boster) control ~58% share, yet catalog overlap is low, giving late entrants room to differentiate on recombinant clonality and carrier-free formats.

Long-term, demand will outstrip supply unless vendors invest in high-density perfusion bioreactors; our model shows a 9% CAGR supply shortfall after 2026. Innovation is shifting to site-specific conjugation and rabbit-monoclonal platforms, raising technical barriers and customer stickiness.

Key risks include batch-to-batch variability, rising import tariffs on research reagents, and uncertain NIH funding cycles that could compress academic budgets. Overall, the space rewards players with disciplined QC and agile logistics; pure-price strategies will erode value quickly.

12 items

1. Executive Summary

2. DCAF13 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global DCAF13 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global DCAF13 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global DCAF13 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global DCAF13 Antibody Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.3. Global DCAF13 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global DCAF13 Antibody Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global DCAF13 Antibody Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global DCAF13 Antibody Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.3. Global DCAF13 Antibody Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global DCAF13 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global DCAF13 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global DCAF13 Antibody Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global DCAF13 Antibody Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Type

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Type

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Type

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Type

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Type

9. Global DCAF13 Antibody Market Competition by Key Manufacturers

9.1. Global DCAF13 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global DCAF13 Antibody: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bioss

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Abcam

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. LSBio

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. OriGene Technologies

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Biorbyt

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. ProSci

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. United States Biological

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. GeneTex

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Creative Biolabs

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Thermo Fisher Scientific

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global DCAF13 Antibody Market

Figure 4: Global DCAF13 Antibody Market: Drivers

Figure 5: Global DCAF13 Antibody Market: Challenges

Figure 6: Global DCAF13 Antibody Market: Trends

Figure 7: Global DCAF13 Antibody Market: Opportunity

Figure 8: Global DCAF13 Antibody Market: Restraint

Figure 9: Global DCAF13 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Type

Figure 17: Global Market Share (%) By Type (2024)

Figure 18: Global DCAF13 Antibody Market Value (USD Million) By Region

Figure 19: Global DCAF13 Antibody Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Type

Figure 25: Global Market Share (%) By Type (2032)

Figure 26: Global DCAF13 Antibody Market Value (USD Million) By Region

Figure 27: Global DCAF13 Antibody Market Share (%) By: Regions (2032)

Figure 28: Global DCAF13 Antibody Market Volume (K) By Region

Figure 29: Global DCAF13 Antibody Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Type

Figure 35: Global Market Share (%) By Type (2032)

Figure 36: Global DCAF13 Antibody Market Value (USD Million) By Region

Figure 37: Global DCAF13 Antibody Market Share (%) By: Regions (2032)

Figure 38: Global DCAF13 Antibody Market Volume (K) By Region

Figure 39: Global DCAF13 Antibody Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global DCAF13 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global DCAF13 Antibody Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global DCAF13 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Type

Table 12: Global Market Share (%) By Type (2024)

Table 13: Global DCAF13 Antibody Market Value (USD Million) By Region

Table 14: Global DCAF13 Antibody Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Type

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Type

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Type

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 30: Global DCAF13 Antibody Market Volume (K) By Region

Table 31: Global DCAF13 Antibody Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Type

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Type

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Type

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 47: Global DCAF13 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global DCAF13 Antibody Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global DCAF13 Antibody Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bioss Basic Information And Sales Area

Table 52: Bioss. Products Portfolio

Table 53: Abcam Basic Information And Sales Area

Table 54: Abcam. Products Portfolio

Table 55: LSBio Basic Information And Sales Area

Table 56: LSBio. Products Portfolio

Table 57: OriGene Technologies Basic Information And Sales Area

Table 58: OriGene Technologies. Products Portfolio

Table 59: Biorbyt Basic Information And Sales Area

Table 60: Biorbyt. Products Portfolio

Table 61: ProSci Basic Information And Sales Area

Table 62: ProSci. Products Portfolio

Table 63: United States Biological Basic Information And Sales Area

Table 64: United States Biological. Products Portfolio

Table 65: GeneTex Basic Information And Sales Area

Table 66: GeneTex. Products Portfolio

Table 67: Creative Biolabs Basic Information And Sales Area

Table 68: Creative Biolabs. Products Portfolio

Table 69: Thermo Fisher Scientific Basic Information And Sales Area

Table 70: Thermo Fisher Scientific. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Type

Table 74: Global Market Share (%) By Type (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global DCAF13 Antibody Market Value (USD Million) By Region

Table 80: Global DCAF13 Antibody Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Type

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Type

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Type

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 96: Global DCAF13 Antibody Market Volume (K) By Region

Table 97: Global DCAF13 Antibody Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Type

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Type

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Type

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current DCAF13 Antibody market size?

Global DCAF13 Antibody market size surpassed USD 180 million in 2023, underpinned by rising proteomics spend and targeted oncology research that keeps reagent demand on an upward trajectory.

2. How fast will the market grow through 2030?

Conservative models project an 11–13% CAGR, lifting the DCAF13 Antibody market to roughly USD 420 million by 2030, driven by biomarker discovery and multiplex immunoassay adoption.

3. What are the key demand drivers?

Expanded cancer genomics, CRISPR validation workflows, and high-affinity rabbit recombinants collectively accelerate procurement, while NIH funding boosts DCAF13 Antibody consumption in translational labs.

4. Which challenges restrain faster uptake?

Epitope cross-reactivity questions, batch-to-batch variability, limited off-the-shelf SKUs, and high import tariffs in price-sensitive countries temper the otherwise bullish future outlook for DCAF13 Antibody suppliers.

5. Which region leads consumption?

North America accounts for ~42% share, fueled by NCI grants and CRO clusters, followed by Europe’s 28%, while China is racing to dominate APAC’s fastest-growing segment.

6. Who are the top companies?

Abcam, Thermo Fisher, Santa Cruz Biotechnology, Genetex, and Atlas Antibodies lead; each offers validated DCAF13 Antibody pairs, custom conjugation, and GMP-grade formats for IVD partners.

7. What future opportunities exist?

Companion diagnostic co-development, multi-omics panels, and lysine-acetylation focused drug screens present untapped revenue pockets, especially if bundled with AI-guided epitope mapping services.

8. How is technology reshaping supply?

Recombinant rabbit platforms, high-throughput phage display, and in-silico cross-reactivity screening shorten lead times, improve reproducibility, and widen the DCAF13 Antibody market size potential.

9. Which regulations impact market entry?

FDA’s ASR and IVDR classifications in Europe demand enhanced affinity data, ISO 13485 certification, and post-market surveillance, raising compliance costs yet consolidating share among compliant DCAF13 Antibody vendors.

Contact for Full Report

Loading report content...

DCAF13 Antibody Size, Share & Forecast Analysis 2025–2033

Market Snapshot

DCAF13 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

DCAF13 Antibody Segmentation

DCAF13 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current DCAF13 Antibody market size?

2. How fast will the market grow through 2030?

3. What are the key demand drivers?

4. Which challenges restrain faster uptake?

5. Which region leads consumption?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology reshaping supply?

9. Which regulations impact market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

DCAF13 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

DCAF13 Antibody Segmentation

DCAF13 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current DCAF13 Antibody market size?

2. How fast will the market grow through 2030?

3. What are the key demand drivers?

4. Which challenges restrain faster uptake?

5. Which region leads consumption?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology reshaping supply?

9. Which regulations impact market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation